Skip to main content

Table 3 The Association between HLA-B*58:01 allele and SNPs with allopurinol-induced cADRs

From: Influence of pharmacogenomic polymorphisms on allopurinol-induced cutaneous adverse drug reactions in Thai patients

HLA/SNPs allele

cADRs vs. tolerant control

SJS/TEN vs. tolerant control

DRESS vs. tolerant control

MPE vs. tolerant control

Odds ratio

(95% CI)

P-value

Odds ratio

(95% CI)

P-value

Odds ratio

(95% CI)

P-value

Odds ratio

(95% CI)

P-value

HLA-B*58:01

137.2

(38.3–670.5)

1.7 × 10− 27

582.0 (62.2–5447.3)

3.7 × 10− 23

92.2

(22.6–375.1)

2.3 × 10− 14

63.7

(8.4–829.2)

2.7 × 10− 6

BAT1

rs2734583, A > G

43.5

(15.6–140.6)

4.4 × 10− 20

90.1

(20.7–580.1)

1.4 × 10− 15

47.6

(12.8–219.8)

1.5 × 10− 12

7.8

(1.0–51.0)

2.5 × 10− 2

BAT3

rs3117583, A > G

10.4

(4.6–24.7)

1.8 × 10− 10

20.5

(6.3–80.3)

2.07 × 10− 9

7.3

(2.5–22.0)

5.2 × 10− 5

5.2

(0.9–31.1)

3.6 × 10− 2

CCHCR1

rs130077, G > A

67.8

(22.9–234.9)

1.1 × 10− 23

287.6

(37.6–12034.6)

1.5 × 10− 18

47.6

(12.8–219.8)

1.5 × 10− 12

20.9

( 3.3–164.6)

3.2 × 10− 4

CCHCR1

rs9263745, G > A

77.7

(25.5–276.4)

1.1 × 10− 24

287.6

(37.6–12034.6)

1.5 × 10− 18

47.6

(12.8–219.8)

1.5 × 10− 12

37.2

(5.4–436.9)

2.1 × 10− 5

CCHCR1

rs9263785, T > G

67.8

(22.9–234.9)

1.1 × 10− 23

287.6

(37.6–12034.6)

1.5 × 10− 18

47.6

(12.8–219.8)

1.5 × 10− 12

20.9

( 3.3–164.6)

3.2 × 10− 4

HCP5

rs3099844, C > A

41.8

(15.3–129.7)

3.7 × 10− 20

40.1

(10.3–234.6)

6.7 × 10− 12

27.5

(7.8–126.1)

2.7 × 10− 10

5.6

(0.9–33.6)

2.9 × 10− 2

HCP5

rs3131643, G > A

23.3

(9.5–62.3)

2.1 × 10− 16

78.7

(18.5–495.9)

5.2 × 10− 15

54.2

(14.0–275.4)

3.4 × 10− 13

6.8

(0.9–43.1)

3.2 × 10− 2

HLA-C

rs4084090, A > G

47.9

(17.3–150.3)

1.1 × 10− 21

181.9

(25.3–7691.2)

2.4 × 10− 16

38.7

(10.6–185.4)

8.2 × 10− 12

13.0

(2.2–95.7)

1.6 × 10− 3

MSH5

rs1150793, A > G

9.1

(4.1–20.9)

1.2 × 10− 9

16.7

(5.3–64.5)

1.7 × 10− 8

5.9

(2.1–17.5)

2.2 × 10− 4

4.2

(0.7–24.9)

5.9 × 10− 2

POLR2LP

rs9263733, C > T

96.1

(29.4–390.8)

1.4 × 10− 25

395.2

(49.0–16306.3)

7.1 × 10− 20

66.9

(16.6–345.1)

1.1 × 10− 13

29.4

(4.3–247.9)

1.06 × 10− 4

POU5F1

rs9263796, C > T

67.8

(22.9–234.9)

1.1 × 10− 23

287.6

(37.6–120 34.6)

1.5 × 10− 18

47.6

(12.8–219.8)

1.5 × 10− 12

20.9

( 3.3–164.6)

3.2 × 10− 4

PSORS1C1

rs2233945, C > A

60.0

(20.6–203.6)

9.7 × 10− 23

287.6

(37.4–12034.6)

1.5 × 10− 18

37.9

(10.6–160.2)

1.8 × 10− 11

20.9

( 3.3–164.6)

3.2 × 10− 4

PSORS1C1

rs9263726, G > A

67.8

(22.9–234.9)

1.1 × 10− 23

287.6

(37.6–12034.6)

1.5 × 10− 18

47.6

(12.8–219.8)

1.5 × 10− 12

20.9

( 3.3–164.6)

3.2 × 10− 4

TCF19

rs1044870, C > T

Inf

(7.3 - Inf)

2.0 × 10− 7

Inf

(0.8 - Inf)

3.8 × 10− 2

Inf

(9.3 - Inf)

6.2 × 10− 7

Inf

(11.4 - Inf2)

1.3 × 10− 5

TCF19

rs9263794, A > G

43.53

(15.9–134.2)

5.3 × 10− 21

165.81

(23.3–7019.3)

6.9 × 10− 16

35.2

(9.7–166.5)

2.1 × 10− 11

11.87

(2.0–86.3)

2.2 × 10− 3

  1. Abbreviations cutaneous adverse drug reactions, cADRs; Stevens - Johnson syndrome, SJS; toxic epidermal necrolysis, TEN; drug reaction with eosinophilia and systemic symptoms, DRESS; maculopapular exanthema, MPE; 95% confidence interval, 95% CI; and single nucleotide polymorphisms, SNPs